| Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells. | None |
| Human c-fms proto-oncogene: comparative analysis with an abnormal allele. | None |
| Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. | None |
| Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q- syndrome. | None |
| Subcellular localization of glycoproteins encoded by the viral oncogene v-fms. | None |
| Chromosomal localization of the human c-fms oncogene. | None |
| Tyrosine 807 of the v-Fms oncogene product controls cell morphology and association with p120RasGAP. | None |
| Isolation of new oncogenic forms of the murine c-fms gene. | None |
| Repression of the CSF-1 receptor (c-fms proto-oncogene product) by antisense transfection induces G1-growth arrest in L6 alpha 1 rat myoblasts. | None |
| The first intron of human c-fms proto-oncogene contains a processed pseudogene (RPL7P) for ribosomal protein L7. | None |
| Autoimmune-thrombocytopenia and SLE in a patient with 5q-anomaly and deletion of the c-fms oncogene. | None |
| Modulation of c-myc, c-myb, c-fos, c-sis and c-fms proto-oncogene expression and of CSF-1 transcripts and protein by phorbol diester in human malignant histiocytosis DEL cell line with 5q 35 break point. | None |
| Reassessment of the murine c-fms proto-oncogene sequence. | None |
| Tyrosine phosphorylation of the juxtamembrane domain of the v-Fms oncogene product is required for its association with a 55-kDa protein. | None |
| Activation of a Ca2+-dependent K+ current by the oncogenic receptor protein tyrosine kinase v-Fms in mouse fibroblasts. | None |